Gene and Cell Therapies for Beta-Globinopathies / Najlacnejšie knihy
Gene and Cell Therapies for Beta-Globinopathies

Kod: 16402079

Gene and Cell Therapies for Beta-Globinopathies

Autor Md Malik, Ph. D. Tisdale

Hemoglobin defects, specifically sickle cell disease & thalassemia, combined, constitute the most common monogenic disorders in the world. In fact, nearly 2% of the world's population carries a globin gene mutation. The transfer o ... więcej

188.91


Dostępna u dostawcy w małych ilościach
Wysyłamy za 10 - 15 dni

Potrzebujesz więcej egzemplarzy?Jeżeli jesteś zainteresowany zakupem większej ilości egzemplarzy, skontaktuj się z nami, aby sprawdzić ich dostępność.


Dodaj do schowka

Zobacz książki o podobnej tematyce

Bon podarunkowy: Radość gwarantowana

Wzór bonu podarunkowegoDowiedz się więcej

Więcej informacji o Gene and Cell Therapies for Beta-Globinopathies

Za ten zakup dostaniesz 467 punkty

Opis

Hemoglobin defects, specifically sickle cell disease & thalassemia, combined, constitute the most common monogenic disorders in the world. In fact, nearly 2% of the world's population carries a globin gene mutation. The transfer of the corrective globin gene through the HSC compartment by allogeneic HSC transplantation (HSCT) has already proven curative in both SCD and thalassemia patients, and provides the proof of concept that genetic manipulation of the defective organ might be equally therapeutic. However, procedural toxicities and the requirement of an HLA-matched sibling donor limit this approach to a fraction of affected individuals. The editors review the progress & the state of the field in HSCT for hemoglobinopathies & shed light on the major changes expected in the next decade. Although allogeneic HSCT is a curative option, it is limited by the availability of matched donors, which are often available only to 15-20% of patients. An alternative to allogeneic HS CT is genetic correction of autologous HSCs, to overcome donor availability & immune side effects. This Book reviews the progress made on additive gene therapy approaches & the current state of the field. Finally, targeted genetic correction is emerging as a novel therapeutic strategy in the hemoglobinopathies. Although ideal, the inefficiency of targeted correction was rate limiting for translation of this technology to the clinic. With advancements in zinc finger nucleases and TALE endonuclease mediated targeted correction, correction frequencies in hematopoietic stem cells is now reaching levels that may become clinically relevant. Furthermore, the ability to generate autologous embryonic stem cell like cells from primary somatic cells (skin fibroblasts or hematopoietic cells) of the affected individual has allowed for the potential application of genetic correction strategies.This Book reviews upcoming genetic strategies to reactivate fetal hemoglobin production and research advances.

Szczegóły książki

Kategoria Książki po angielsku Medicine Pre-clinical medicine: basic sciences Medical genetics

188.91

Ulubione w innej kategorii



Osobní odběr Bratislava a 2642 dalších

Copyright ©2008-24 najlacnejsie-knihy.sk Wszelkie prawa zastrzeżonePrywatnieCookies


Konto: Logowanie
Všetky knihy sveta na jednom mieste. Navyše za skvelé ceny.

Nákupní košík ( prázdný )

Nakupte za 59,99 € a
máte doručení zdarma.

Twoja lokalizacja: